The age-related decline in circulating Ihh and its strong association with metabolic health suggest that enhancing Ihh signaling may represent a novel therapeutic avenue for obesity and type 2 diabetes. Here, IHH is linked to obesity due to melanocortin 4 receptor deficiency.